

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed ID6647**

**Provisional Stakeholder List**

| <b>Provisional Consultees</b>  | <b>Provisional Commentators (no right to submit or appeal)</b>  |
|--|---|
| <p><u>Company</u><br/>Merck Serono (pimicotinib)</p> <p><u>Patient/carers groups</u></p> <ul style="list-style-type: none"> <li>Action on Pain</li> <li>Arthritis and Musculoskeletal Alliance</li> <li>Pain Concern</li> <li>Pain UK</li> <li>Sarcoma UK</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>British Association for Surgery of the Knee</li> <li>British Orthopaedic Association</li> <li>British Orthopaedic Foot and Ankle Society</li> <li>British Orthopaedic Oncology Society</li> <li>British Pain Society</li> <li>British Sarcoma Group</li> <li>Physiotherapy Pain Association</li> <li>Primary Care Rheumatology and Musculoskeletal Medicine Society</li> <li>British Society for Surgery of the Hand</li> <li>British Society of Rheumatology</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Amarox (imatinib)</li> <li>Cipla EU (imatinib)</li> <li>Dr. Reddy's Laboratories (imatinib)</li> <li>Grindeks Kalceks (imatinib)</li> <li>Novartis (imatinib, nilotinib)</li> <li>Orion Pharma (imatinib)</li> <li>Sandoz (imatinib)</li> <li>Zentiva (nilotinib)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Cochrane Musculoskeletal Group</li> <li>Bone Cancer Research Trust</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul> |

Provisional stakeholder list for the evaluation of pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed ID6647

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 1 of 3

| Provisional Consultees   | Provisional Commentators (no right to submit or appeal)  |
|--|--|
| <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Bone and Soft Tissue Tumour Service, Newcastle Hospitals NHS Foundation Trust</li> <li>• Department of Health and Social Care</li> <li>• Greater Manchester and Oswestry Sarcoma Service, The Christie NHS Foundation Trust</li> <li>• NHS England</li> <li>• Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust</li> <li>• Oxford Sarcoma Service, Oxford University Hospitals NHS Foundation Trust</li> <li>• Robert Jones and Angles Hunt Orthopaedic Hospital NHS Foundation Trust</li> <li>• Royal National Orthopaedic Hospital NHS Trust</li> <li>• The Royal Marsden NHS Foundation Trust</li> <li>• The Royal Orthopaedic Hospital NHS Foundation Trust</li> </ul> | <ul style="list-style-type: none"> <li>• Orthopaedic Research UK</li> <li>• Pain Relief Foundation</li> <li>• The Society for Research in Rehabilitation</li> <li>• Wellcome Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul> |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

## Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.